AstraZeneca Might Pay $340 Million to Avanir
From Bloomberg News
AstraZeneca will pay as much as $340 million to Avanir Pharmaceuticals to develop experimental heart-disease treatments.
The companies will work to develop medicines from so-called reverse cholesterol transport enhancing compounds, which may allow the body to reverse damage to blood vessels, AstraZeneca said.
AstraZeneca will pay $10 million now with as much as $330 million linked to the experimental drugs meeting development goals, the companies said. San Diego-based Avanir may get low double-digit royalties from sales of the drugs.
